Celyad Oncology S.A.

CLYYF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-$3,700-$2,780-$3,044-$4,708
Dep. & Amort.$0$221$229$397
Deferred Tax$0$0$0$0
Stock-Based Comp.$0-$6$6$491
Change in WC$0-$483$306$2,394
Other Non-Cash$3,700$199-$328-$5,445
Operating Cash Flow$0-$2,849-$2,831-$6,871
Investing Activities
PP&E Inv.$0-$118-$118-$583
Net Acquisitions$0$15$0$26
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$118$0-$1
Investing Cash Flow$0$15-$118-$558
Financing Activities
Debt Repay.$0$83-$83$0
Stock Issued$0$0$0$9,490
Stock Repurch.$0$0$0$10
Dividends Paid$0$0$0$0
Other Fin. Act.$0$725$2,258-$43
Financing Cash Flow$0$808$2,175$9,457
Forex Effect$0-$4$0$0
Net Chg. in Cash$0-$2,029-$775$2,028
Supplemental Information
Beg. Cash$0$6,229$7,004$4,976
End Cash$0$4,200$6,229$7,004
Free Cash Flow$0-$2,849-$2,831-$7,454